INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) investors concerning the Company’s possible violations of federal securities laws.

On December 6, 2021, the FDA released a briefing document regarding Reata’s chronic kidney disease drug candidate, bardoxolone methyl. Therein, the FDA stated that the data submitted by Reata did not “demonstrate that bardoxolone is effective in slowing the loss of kidney function in patients with [Alport syndrome].”

On this news, Reata’s share price fell $29.77, or 37.8%, to close at $48.92 per share on December 6, 2021, thereby injuring investors.

If you purchased Reata securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at [phone], toll-free at [phone], or by email to [e-mail], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.